ScienceOpen: research and publishing network

For Researchers

Search
Advanced search

2

views

    

0

recommends

0

shares

Record: found
Abstract: found
Article: not found

Everolimus-induced epithelial to mesenchymal transition (EMT) in bronchial/pulmonary cells: when the dosage does matter in transplantation.

Author(s): Paola Tomei, Valentina Masola, Simona Granata, Gloria Bellin, Pierluigi Carratù, Miriam Ficial, Valentina Anna Ventura, Maurizio Onisto, Onofrio Resta, Giovanni Gambaro, Marco Chilosi, Antonio Lupo, Gianluigi Zaza

Publication date: 2016-12-01

Journal: Journal of nephrology

Publisher: Springer Nature America, Inc

Keywords: Fibrosis, Pulmonary cells, Lung, mTOR inhibitor, Epithelial-mesenchymal transition, Everolimus, Cystic fibrosis

Read this article at

ScienceOpenPublisher PubMed

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Everolimus (EVE) is a mammalian target of rapamycin inhibitor (mTOR-I) widely used in transplantation that may determine some severe adverse events, including pulmonary fibrosis. The pathogenic mechanism of mTOR-I-associated pulmonary toxicity is still unclear, but epithelial to mesenchymal transition (EMT) of bronchial/pulmonary cells may play a role.

Related collections

Author and article information

Journal

PubMed ID:: 27026415

DOI:: 10.1007/s40620-016-0295-4

Keywords: Fibrosis,Pulmonary cells,Lung,mTOR inhibitor,Epithelial-mesenchymal transition,Everolimus,Cystic fibrosis

Data availability:

Keywords: Fibrosis, Pulmonary cells, Lung, mTOR inhibitor, Epithelial-mesenchymal transition, Everolimus, Cystic fibrosis

Comments

Comment on this article

scite_